Qube Research & Technologies LTD Protagonist Therapeutics, Inc Transaction History

Qube Research & Technologies LTD

$82.3 Billion
Q1 2025

A detailed history of Qube Research & Technologies LTD transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Qube Research & Technologies LTD holds 343,411 shares of PTGX stock, worth $17.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

343,411

Previous 312,319 9.96%

Holding current value

$17.2 Million

Previous $12.1 Million 37.76%

% of portfolio

0.02%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$35.09 - $59.76 $1.09 Million - $1.86 Million	31,092 Added 9.96%	343,411 $16.6 Million
Q4 2024 Feb 14, 2025	SELL	$38.51 - $48.43 $410,901 - $516,748	-10,670 Reduced 3.3%	312,319 $12.1 Million
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $4.39 Million - $6.16 Million	-130,163 Reduced 28.72%	322,989 $14.5 Million
Q2 2024 Aug 14, 2024	BUY	$24.66 - $34.8 $9.64 Million - $13.6 Million	390,997 Added 629.07%	453,152 $15.7 Million
Q1 2024 May 14, 2024	BUY	$21.79 - $32.15 $1.35 Million - $2 Million	62,155 New	62,155 $1.8 Million
Q3 2023 Nov 13, 2023	BUY	$16.68 - $23.66 $1.53 Million - $2.17 Million	91,735 New	91,735 $1.53 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $327,004 - $496,283	44,430 Added 48.68%	135,706 $1.48 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $717,429 - $1.07 Million	91,276 New	91,276 $769,000
Q2 2021 Aug 13, 2021	SELL	$25.57 - $44.88 $344,300 - $604,309	-13,465 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$19.02 - $31.15 $256,104 - $419,434	13,465 New	13,465 $349,000

Others Institutions Holding PTGX

# of Institutions

299

Shares Held

61.3M

Call Options Held

1.01M

Put Options Held

555K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.47B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Protagonist Therapeutics, Inc Transaction History